阿斯特捷利康與Immunai達成8,500萬美元新合作推進發炎性腸道疾病全新療法

2025-10-17 / 記者吳康瑋

美國時間16日，阿斯特捷利康(AstraZeneca)宣布，與其人工智慧合作夥伴Immunai達成一項價值高達8,500萬美元的全新協議，主要是為了推進一種新型發炎性腸道疾病(IBD)療法的合適標靶。根據資料顯示，Immunai公司總部位於美國紐約，主要利用其先進的AMICA細胞圖譜和名為「免疫動力學引擎」(ImmunodynamicsEngine)的人工智慧模型，成功確定了該療法的目標標靶。該模...

GBIHighlights Immunotherapy Antibodies Oncology

AP Biosciences advances next-generation bispecific antibody therapies for solid tumor immunotherapy

2025-09-22 / GlobalBio & Investment

APBiosciences,Inc.isadvancingnext-generationCD137bispecificantibodytherapiesforsolidtumorimmunotherapy. AttheTaiwanImmuno-OncologyDrugDevelopmentForum,founderDr.JengHersharedhowAPBiosciencesisdifferen...

GBIHighlights Oncology mRNA Immunotherapy

Elixiron Targets T-Cell Exhaustion with Next-Gen Cancer Immunotherapies

2025-09-18 / GlobalBio & Investment

On16thSeptember,Dr.Hung-KaiChen,Founder&CEOofElixironImmunotherapeutics,sharedthecompany’sinnovativepipelineaddressingoneofthetoughestchallengesinoncology—TcellexhaustionattheTaiwanImm...

GBIHighlights ICI Immunotherapy Oncology

GNT Biotech Advances GNTbm-38 with IND Filings in US & China by 2026

2025-09-18 / GlobalBio & Investment

GNTBiotech&MedicalsCorporation(GNTbm)isadvancingGNTbm-38,anext-generationoralimmuno-regulatorydrug,withINDfilingsplannedintheUS&Chinabyearly2026.InvestmentHighlightsGlobalIPStrength:38inventio...

細胞治療實體癌 TCR-T 肉瘤

岌岌可危！TCR-T療法先驅Adaptimmune驚傳8500萬美元出售核心資產

2025-07-30 / 記者吳培安

美國時間28日，英國細胞治療公司Adaptimmune宣布將其開發的已獲批T細胞受體T(TCR-T)療法Tecelra(afami-cel)與兩項臨床開發中的細胞治療資產，以8500萬美元出售給美國USWorldMeds，以挽救公司當前營運的危機。消息公布後，Adaptimmune股價大幅下跌2/3，當日下午交易股價僅有每股10美分。 Tecelra是美國食品藥物管理局(FDA)首度批准用於實體癌...

GBIHighlights

The Future of CGT: Gene Editing, Hypoimmune Platforms & Decentralized Manufacturing

2025-07-27 / GlobalBio & Investment

Atthe2025BIOAsia–TaiwanInnovationForumSA-2,leadingU.S.-basedexpertsinadvancedgeneandcelltherapygatheredtosharecutting-edgetechnologiesandcommercializationstrategiesthatareredefiningthefutureofCG...

個股資訊

安特羅(6564)：ENIMMUNE-RMT BIOTECH獲通知減資變更登記完成

2025-07-02 / 環球生技

本資料由　 (興櫃公司)6564安特羅　公司提供序號 1 發言日期 114/07/02 發言時間 17:33:20發言人李家卉發言人職稱協理發言人電話 02-27001216主旨代重要子公司ENIMMUNE-RMTBIOTECHPTE.LTD.公告辦理減資變更登記完成符合條款第 35 款事實發生日 114/07/02說明...

個股資訊

安特羅(6564)：ENIMMUNE-RMT BIOTECH董事會通過辦理現金減資45%

2025-05-15 / 環球生技

本資料由　(興櫃公司)6564安特羅　公司提供序號 2 發言日期 114/05/14 發言時間 18:23:55發言人李家卉發言人職稱協理發言人電話 02-27001216主旨代子公司ENIMMUNE-RMTBIOTECHPTE.LTD.公告董事會決議通過辦理現金減資案符合條款第 9款事實發生日 114/05/14說明 1...

GBIHighlights AntibodyPioneer ChangTseWen Immunwork

Taiwan’s Father of Antibodies, Dr. Chang Tse Wen: “Small Companies Can Dream Big in Drug Development

2025-03-24 / GlobalBio & Investment

ImmunworkInc.hasspent10yearsperfectingitsbreakthroughtherapies,withtwoultra-long-actingpeptidedrugsnowinclinicaltrials!Thecompanyisontrackforapotentialpubliclistingbylate2025or2026! PipelineHighlights...

GBIHighlights KOL Sytwu NHRI Immunology

How a Major General-Turned-CEO is Driving Translational Medicine in Taiwan!

2025-03-21 / GlobalBio & Investment

Huey-KangSytwu,aleaderfromTaiwan’smilitarymedicalsystem,maycarrythecommandingpresenceofageneral,butinbiotechcircles,heisknownforhiswarmth—alwaysgreetingotherswithahumblebowandafriendlychat...

GBIHighlights CancerTherapy Immunotherapy

Taking on 5 Cancers? This Biotech Aims for 2025 IPO!

2025-03-08 / GlobalBio & Investment

HanchorBio,ledbyChairmanDr.ScottLiu,isbreakingbarriersintumorimmunotherapy!WithitsB-roundfundingsecuredin2024,thecompanyissettoadvanceHCB101intoPhase1b/2aclinicaltrialsinQ12025,targetingfivetypesofcan...

GBIHighlights ProtectBio PetHealth AnimalCancer Immunotherapy

Protect Companion Pet's Healthcare

2025-02-17 / GlobalBio & Investment

Didyouknowthatpets,likehumans,cangetcancer?Thisbiotechcompany,ProtectBiotech (alsoknownasProtectAnimalHealthInc),isdevelopingcancerimmunotherapyforanimals,includingabroad-spectrumPD-L1/CTLA-4vaccinefo...